Jonathan Symonds Buys 5,000 Shares of GSK (LON:GSK) Stock

Key Points

• Jonathan Symonds bought 5,000 GSK shares on March 20 at GBX 1,951 each (≈£97,550) and had previously acquired 2,500 shares on Feb 5 at GBX 2,114 (≈£52,850).
• GSK shares recently fell 0.6% to GBX 1,939, with a market cap of £77.78 billion, a P/E of 13.97 and a 52‑week range of GBX 1,242.50–2,282.
• Analysts are divided (three Buy, three Hold, one Sell) with an average target of GBX 1,917.86; GSK reported GBX 172 EPS last quarter and is forecast to post ~176 EPS for the year.

GSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds purchased 5,000 shares of GSK stock in a transaction on Friday, March 20th. The stock was bought at an average price of GBX 1,951 per share, with a total value of £97,550.

Jonathan Symonds also recently made the following trade(s):

• On Thursday, February 5th, Jonathan Symonds acquired 2,500 shares of GSK stock. The shares were bought at an average price of GBX 2,114 per share, for a total transaction of £52,850.

GSK Stock Down 0.6%

Shares of LON GSK traded down GBX 11.50 during trading on Monday, hitting GBX 1,939. 886,705,000 shares of the company traded hands, compared to its average volume of 25,118,266. The firm has a market capitalization of £77.78 billion, a price-to-earnings ratio of 13.97, a P/E/G ratio of 1.24 and a beta of 0.32. The business's fifty day moving average is GBX 2,024.84 and its 200 day moving average is GBX 1,817.34. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82. GSK plc has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 2,282.

GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. Equities research analysts predict that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on GSK. UBS Group reaffirmed a "neutral" rating and set a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. Citigroup lifted their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a "buy" rating in a research report on Monday, February 9th. Jefferies Financial Group restated a "buy" rating and set a GBX 2,100 price objective on shares of GSK in a report on Wednesday, January 7th. Shore Capital Group reaffirmed a "buy" rating and issued a GBX 2,300 price objective on shares of GSK in a research note on Wednesday, February 4th. Finally, Berenberg Bank lifted their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a "hold" rating in a report on Monday, November 24th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, GSK currently has an average rating of "Hold" and an average target price of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.